Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib maintenance with or without bevacizumab after first-line paclitaxel-carboplatin in advanced ovarian cancer
2021-004278-76Phase 2Active
- Sponsor
- Arcagy-Gineco
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of niraparib, bevacizumab, paclitaxel and carboplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoint: Progression-free survival rate at 24 months. Started Sep 2021; status: active.
02
Drugs
niraparibbevacizumabpaclitaxelcarboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-004278-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004278-76.